Whalesbook
A Growing Threat to Farms
The rapid spread of a new highly pathogenic avian influenza (HPAI) strain, HPAI A(H5N1) D1.1, across North America is no longer just a public health worry; it's a major economic problem. This new virus type is severely testing global farming markets, the readiness of pharmaceutical defenses, and how well economies can handle biological threats.
The Fast-Evolving Virus
The HPAI A(H5N1) D1.1 strain is spreading very quickly, largely replacing older versions in North America by late 2024. Scientists discovered this strain during the fall migration, noting its spread across all four major North American bird flyways. Genetic analysis shows it has a specific North American-made part that may help it evade immune responses, meaning people are less immune to it compared to earlier strains. While the virus is consistently found replicating in mammals, including U.S. dairy cattle, markers suggesting adaptation to mammals have appeared in infected people. These seem to have developed in humans, rather than being transmitted directly from wild birds. The virus has also developed resistance to some antiviral drugs, like oseltamivir, showing it's constantly changing its threat.
Heavy Toll on Farms
The quick spread of HPAI D1.1 has caused significant economic damage across the farming sector, hitting poultry and dairy the hardest. The U.S. egg industry, in particular, has faced severe disruptions. Outbreaks in 2024-2025 alone are estimated to have cost American consumers an extra $14.5 billion, effectively doubling annual egg spending. Globally, HPAI losses since 2003 amount to billions, greatly affecting poultry production and trade. The dairy sector is also under considerable strain. An outbreak in a single U.S. dairy herd was estimated to cost $737,500, mostly from lost milk production, which makes up over 90% of the economic damage in affected herds. In the United States, HPAI in dairy cattle could lead to dairy production losses ranging from 3.4% to over 20.6% and potentially reduce national GDP by 0.9% in the worst scenarios. Travel and trade bans during outbreaks, though somewhat eased by agreements on affected zones, continue to disrupt global meat and dairy markets, leading to substantial export declines and revenue losses for producers.
Gaps in Pandemic Readiness
Despite the growing threat from evolving avian influenza strains and their broad economic impact, overall investment in pandemic readiness appears to be shrinking. While markets for specific bird flu vaccines and antiviral drugs are strong—the global avian influenza vaccine market was valued at $152.01 billion in 2024 and is projected to grow—wider public health systems face less funding. The G20 estimates a major annual funding gap of at least $10.5 billion for complete pandemic preparedness plans, and U.S. investments are also decreasing. This contrast shows a problem: companies focus on specific problems, but the necessary public services for broad preparedness are underfunded, creating risks for the whole system.
Key Risks and Concerns
- Viral Adaptability: The emergence of the D1.1 strain, its quick dominance, and resistance to antivirals show how well the virus can adapt. This means current treatments like vaccines and antivirals might need constant upgrades, and could fall behind the virus's changes. Mammal-adaptive markers appearing in human infections, even if they developed in humans, raise concerns about the virus's potential to spread between species more easily over time.
- Animal-to-Human Spread Risk: While direct human-to-human spread of HPAI remains unlikely, the virus's ability to infect and replicate in more types of animals, notably dairy cattle, increases the chances of animal-to-human disease spread. This wider host range, combined with more contact between people and animals on farms, creates opportunities for new ways the disease to spread that could eventually lead to widespread human infections.
- Underfunded Defenses: Global funding for pandemic preparedness has reportedly decreased, creating a vulnerable situation. This drop in investment weakens essential systems for monitoring, quick detection, and fast rollout of treatments. The result is a widening gap between how fast biological threats change and the world's ability to respond comprehensively, leaving economies more exposed to the knock-on effects of future outbreaks.
- Trade Impacts: Even with improved trade resilience through zoning agreements, HPAI continues to add costs to global poultry markets through export bans and strict safety measures. The impact on specific areas like egg farms shows how fragile specialized farm supply chains are, which can experience sudden price swings and shortages when disrupted.
Looking Ahead
The continued evolution of HPAI strains and their presence in wild birds suggest the disease is becoming common, leading to regular seasonal outbreaks. This ongoing threat requires a major change from handling crises as they happen to investing proactively and consistently in strong biosecurity measures, better monitoring technology, and full preparation for farming and public health. Failing to address the economic weaknesses across the system and funding gaps will leave global markets exposed to rising costs from future biological events, turning local outbreaks into major economic crises.